| Name | Title | Contact Details |
|---|
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
Ultracision, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CORHIO is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Denver, CO. To find more information about CORHIO, please visit www.corhio.org
Ryogen is a Suffern, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genia Photonics Inc. is a Lasalle, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.